Karyopharm Therapeutics (KPTI) Receivables - Net (2019 - 2025)
Karyopharm Therapeutics' Receivables - Net history spans 7 years, with the latest figure at $26.2 million for Q4 2025.
- For Q4 2025, Receivables - Net fell 14.91% year-over-year to $26.2 million; the TTM value through Dec 2025 reached $26.2 million, down 14.91%, while the annual FY2025 figure was $26.2 million, 14.91% down from the prior year.
- Receivables - Net reached $26.2 million in Q4 2025 per KPTI's latest filing, down from $31.9 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $47.1 million in Q4 2022 to a low of $17.8 million in Q1 2021.
- Average Receivables - Net over 5 years is $29.5 million, with a median of $30.9 million recorded in 2024.
- Peak YoY movement for Receivables - Net: soared 109.3% in 2022, then plummeted 42.74% in 2023.
- A 5-year view of Receivables - Net shows it stood at $22.5 million in 2021, then skyrocketed by 109.3% to $47.1 million in 2022, then tumbled by 42.74% to $27.0 million in 2023, then grew by 14.11% to $30.8 million in 2024, then decreased by 14.91% to $26.2 million in 2025.
- Per Business Quant, the three most recent readings for KPTI's Receivables - Net are $26.2 million (Q4 2025), $31.9 million (Q3 2025), and $32.9 million (Q2 2025).